AptarGroup, Inc. 10-Q Summary: Quarter Ended March 31, 2001
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2001, for AptarGroup, Inc., a Delaware corporation headquartered in Crystal Lake, Illinois. The company manufactures and sells closure and delivery systems for the fragrance/cosmetics, personal care, food/beverage, and pharmaceutical markets. As of May 8, 2001, there were 35,758,379 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Net Sales | $232.9 million | $217.6 million |
| Operating Income | $31.3 million | $28.6 million |
| Net Income | $18.1 million | $16.3 million |
| Diluted EPS | $0.50 | $0.45 |
| Gross Margin | 37.2% | 38.3% |
| Operating Margin | 13.4% | 13.1% |
| Cash from Operations | $29.2 million | $20.7 million |
| Capital Expenditures | $20.5 million | $16.4 million |
| Cash and Equivalents | $55.7 million | $34.2 million |
| Total Debt (Short + Long Term) | $285.4 million | $292.3 million |
Note: Debt figures include notes payable, current maturities of long-term obligations, and long-term obligations. Net debt to total net capitalization was 34.7% at March 31, 2001.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% year-over-year. Excluding foreign currency translation effects ("Core Sales"), growth was 12%, driven by strong performance in the fragrance/cosmetics and European personal care markets.
- Profitability: Net income rose 11% to $18.1 million. The effective tax rate decreased to 33.4% from 35.4% due to lower corporate tax rates in France and Germany.
- Cost Structure: Cost of sales as a percentage of net sales increased to 62.8% from 61.7%. This was influenced by the consolidation of a former joint venture and product mix changes, partially offset by better fixed cost utilization in Europe.
- Cash Flow: Operating cash flow improved significantly to $29.2 million, aided by reduced cash usage for working capital compared to the prior year.
- Accounting Change: The company adopted SFAS No. 133 regarding derivative instruments, resulting in a cumulative effect adjustment of $(64) thousand to net income.
Guidance, Outlook, and Risks
- Strategic Initiative: Management launched a plan to consolidate pump manufacturing operations to improve efficiency. This is expected to generate over $5 million in annual cash savings by the end of 2002. The initiative involves non-recurring cash outlays of approximately $3 million (primarily labor reduction) and non-cash charges estimated between $6 million and $9 million.
- Full Year Guidance: The company reaffirmed its 2001 earnings per share guidance of $1.95 to $2.05, excluding the non-recurring charges related to the strategic initiative.
- Market Outlook: Demand for fragrance/cosmetic products remains strong. Pharmaceutical sales are expected to improve in the second half of 2001 due to new customer projects.
- Risks: Key risks include foreign currency fluctuations (a stronger U.S. dollar negatively impacts translation), changes in raw material costs, and the successful execution of the strategic initiative. The company maintains a foreign exchange risk management policy but does not engage in speculative hedging.
Investor Verification Checklist
- Verify the timing and magnitude of the $6–9 million non-cash charges related to the manufacturing consolidation initiative.
- Monitor the impact of the stronger U.S. dollar on future quarterly results, particularly regarding European operations.
- Confirm the realization of the projected $5 million annual cash savings from the strategic initiative by the end of 2002.
- Review the company's ability to maintain the 33–34% effective tax rate given international operations.
- Assess the progress of new customer projects in the pharmaceutical sector expected to launch in the second half of 2001.